New chair for NuVision

Roger Teasdale

A new chair has been appointed by ocular tissue-therapy company NuVision Biotherapies. The announcement comes as Mark Treherne steps down from the role to serve as an independent non-executive director after six years of leadership.

Roger Teasdale, who has been a non-executive director at NuVision since 2017, “will bring extensive experience in the healthcare industry to his new role”, said the company. He previously spent more than 25 years at British multinational medical equipment firm, Smith & Nephew, where he served five years as president of the Advanced Wound Management Division.

Commenting on his appointment, Roger said: “It’s a real privilege to take on the role of chair at such an innovative company. My experience as a non-executive director since 2017 has given me a deep understanding of NuVision’s mission and goals. I look forward to building on this foundation as we expand into new markets and bring our transformative eye treatments to more people in need.”

NuVision’s CEO, Andy Hill, added: “It is a privilege to have Roger step into the role of chairman. His deep understanding of NuVision and the industry will be vital as we continue to drive innovation and growth in the UK and internationally. We also want to extend our gratitude to Mark Treherne for his valuable contributions over the past six years.”

Founded on 15 years of research at the University of Nottingham, NuVision Biotherapies pioneers tissue therapy in ophthalmology. The products are currently available in 140 UK hospitals, 30 UK private hospitals and seven countries globally.